While the coronavirus disease 19 (COVID-19) pandemic has transformed the medical and
scientific communites since it was first reported in late 2019, we are only beginning to …

Acute respiratory distress syndrome (ARDS) continues to be a major healthcare problem,
affecting> 190 000 people in the USA annually, with a mortality of 27–45%, depending on …

Sepsis-induced acute respiratory distress syndrome (ARDS) has high morbidity and
mortality and arises after lung infection or infection at extrapulmonary sites. An aberrant host …

The ability of the lung to perform gas exchange is made possible in part by the effective
relationship between the alveolar epithelium and the endothelium of the pulmonary …

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) comprise a
spectrum of acute inflammatory pulmonary oedema resulting in refractory hypoxaemia in the …

Influenza Virus (IV) pneumonia is associated with severe damage of the lung epithelium and
respiratory failure. Apart from efficient host defense, structural repair of the injured epithelium …

Introduction The effectiveness of corticosteroid therapy on the mortality of acute respiratory
distress syndrome (ARDS) remains under debate. We aimed to explore the grounds for the …

The new coronavirus SARS‐CoV‐2 is a global pandemic and a severe public health crisis.
SARS‐CoV‐2 is highly contagious and shows high mortality rates, especially in elderly and …

Acute respiratory distress syndrome (ARDS) is characterised by diffuse alveolar damage
and is frequently complicated by pulmonary hypertension (PH). Multiple factors may …

Despite intense investigation, acute respiratory distress syndrome (ARDS) remains an
enormous clinical problem for which no specific therapies currently exist. In this study, we …